9.63
0.29 (3.10%)
| Previous Close | 9.34 |
| Open | 9.44 |
| Volume | 110,851 |
| Avg. Volume (3M) | 67,352 |
| Market Cap | 127,823,808 |
| Price / Book | 49.98 |
| 52 Weeks Range | |
| Earnings Date | 19 May 2025 - 23 May 2025 |
| Diluted EPS (TTM) | -1.21 |
| Current Ratio (MRQ) | 2.62 |
| Operating Cash Flow (TTM) | -7.27 M |
| Levered Free Cash Flow (TTM) | -1.49 M |
| Return on Assets (TTM) | -180.50% |
| Return on Equity (TTM) | -341.95% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Greenwich LifeSciences, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 3.5 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.5 |
| Average | 1.50 |
|
Greenwich LifeSciences Inc is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. Its Product Candidates include; GP2, a HER2/neu transmembrane peptide that elicits a targeted immune response against HER2/neu-expressing cancers, GM-CSF Immunoadjuvant has been shown to enhance monocyte and neutrophil cytotoxicity against melanoma tumor cells and to enhance activity-dependent cellular cytotoxicity of monocytes and neutrophils against targets coated with the anti-ganglioside antibodies, and Cancer immunotherapy seeks to stimulate an individual’s immune system to selectively attack cancer cells to inhibit the spread of cancer. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 52.54% |
| % Held by Institutions | 9.03% |
| 52 Weeks Range | ||
| Median | 39.00 (304.98%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 21 Apr 2025 | 39.00 (304.98%) | Buy | 9.34 |
| 11 Feb 2025 | 38.00 (294.60%) | Buy | 12.01 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 03 Apr 2025 | Announcement | Greenwich LifeSciences Provides Global Update on FLAMINGO-01 |
| 02 Apr 2025 | Announcement | Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial |
| 27 Mar 2025 | Announcement | Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 |
| 17 Mar 2025 | Announcement | Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 |
| 10 Feb 2025 | Announcement | Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01 |
| 29 Jan 2025 | Announcement | Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe |
| 27 Jan 2025 | Announcement | Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland |
| 23 Jan 2025 | Announcement | Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |